Overview of possible side effects of cosibelimab-UNLOXCYT

Cosibelimab (UNLOXCYT) is a programmed death ligand -1 (PD-L1) blocking antibody that activates the immune system to attack cancer cells by blocking the binding of PD-L1 and PD-1. The drug is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC), particularly those who are not candidates for curative surgery or radical radiotherapy. In December 2024, cosibelimab was officially approved by the U.S. Food and Drug Administration (FDA) and became an important option for the treatment of cutaneous squamous cell carcinoma.

According to clinical trial data, the most common adverse reactions of cosibelimab (incidence≥10%) include:

Fatigue: Patients may feel persistent tiredness or weakness that affects daily life.

Musculoskeletal pain: including muscle soreness, joint pain, etc., which may be related to immune system activation.

Skin rash: The skin may appear erythema, itching, or scaling.

Diarrhea: Some patients may have mild to moderate diarrhea and need to pay attention to replenishing water and electrolytes.

Hypothyroidism: It may cause symptoms such as slowed metabolism, weight gain, fatigue, etc. Regular monitoring of thyroid function is required.

Constipation, nausea, headache: Most of these symptoms are mild and can be relieved by adjusting diet or medication.

Itching and edema: Skin itching or local edema may be related to immune response.

Local infections and urinary tract infections: Activation of the immune system may increase the risk of infection. Pay attention to personal hygiene and preventive measures.

Although the above side effects are mostly mild to moderate, cosibelimab may also cause some serious immune-related adverse reactions, including:

Pneumonia: Symptoms include cough, difficulty breathing, or chest pain, requiring immediate medical attention.

Hepatitis: May cause abnormal liver function, manifested as jaundice, abdominal pain, or loss of appetite.

Colitis: Severe diarrhea, abdominal pain, or blood in the stool may be symptoms of colitis and need to be treated promptly.

Endocrine system abnormalities: such as hyperthyroidism or hypothyroidism, adrenal insufficiency, etc. Hormone levels need to be monitored regularly.

Patients are advised to maintain a healthy diet, moderate exercise and adequate rest to help reduce the impact of side effects. At the same timePatients need to undergo regular blood tests, imaging tests, etc. during treatment to detect potential problems in a timely manner. If severe discomfort or abnormal symptoms occur, you should communicate with your doctor immediately to adjust the treatment plan.

Cosibelimab-UNLOXCYT provides a new treatment option for patients with cutaneous squamous cell carcinoma, but its use may be associated with a range of side effects. Patients should fully understand the potential risks of drugs, conduct treatment under the guidance of a doctor, and pay close attention to their own conditions. Through scientific management and timely intervention, the impact of side effects can be effectively reduced and the safety and effectiveness of treatment can be ensured.

https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of